Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 7
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Challenge models to assess new therapies in chronic obstructive pulmonary disease
Authors van der Merwe, Molfino N
Received 8 February 2012
Accepted for publication 11 June 2012
Published 13 September 2012 Volume 2012:7 Pages 597—605
DOI https://doi.org/10.2147/COPD.S30664
Review by Single anonymous peer review
Peer reviewer comments 2
René van der Merwe,1 Nestor A Molfino2,3
1Respiratory Clinical Development, MedImmune Ltd, Cambridge, UK; 2Respiratory Clinical Development, MedImmune, LLC, Gaithersburg, MD, USA, 3KaloBios Pharmaceuticals, South San Francisco, CA, USA
Abstract: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. Current therapies confer partial benefits either by incompletely improving airflow limitation or by reducing acute exacerbations, hence new therapies are desirable. In the absence of robust early predictors of clinical efficacy, the potential success of novel therapeutic agents in COPD will not entirely be known until the drugs enter relatively large and costly clinical trials. New predictive models in humans, and new study designs are being sought to allow for confirmation of pharmacodynamic and potentially clinically meaningful effects in early development. This review focuses on human challenge models with lipopolysaccharide endotoxin, ozone, and rhinovirus, in the early clinical development phases of novel therapeutic agents for the treatment and reduction of exacerbations in COPD.
Keywords: chronic obstructive pulmonary disease, challenge models, therapy assessment
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.